Perpetual Ltd Boosts Gilead Sciences Stake by 118%

The investment firm increased its position in the biopharmaceutical company during Q4 2025.

Apr. 5, 2026 at 9:33am

Got story updates? Submit your updates here. ›

Perpetual Ltd, an investment management firm, significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 117.9% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 28,498 shares of the biopharmaceutical company's stock, valued at $3.5 million.

Why it matters

Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. The increase in Perpetual Ltd's position suggests the investment firm sees potential growth opportunities in Gilead's product pipeline and future performance.

The details

Perpetual Ltd acquired an additional 15,422 shares of Gilead Sciences during the fourth quarter, bringing its total holdings to 28,498 shares. This represents a 117.9% increase in the firm's position compared to the previous quarter. Gilead Sciences' stock price has seen significant volatility over the past year, trading between $93.37 and $157.29 per share.

  • Perpetual Ltd increased its Gilead Sciences stake during the fourth quarter of 2025.
  • Gilead Sciences' stock price has ranged from $93.37 to $157.29 over the past 52 weeks.

The players

Perpetual Ltd

An investment management firm that significantly increased its stake in Gilead Sciences during the fourth quarter of 2025.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

Perpetual Ltd's increased stake in Gilead Sciences suggests the investment firm sees long-term value in the biopharmaceutical company's portfolio and growth potential. This move highlights the ongoing interest in Gilead Sciences among institutional investors in the healthcare sector.